Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM4B | O94953 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27816449 | 0.88 | ADORA2A (0.45) | ADORA2AADORA1HSP90AA1ADORA3ADORA2B | |
| SCHEMBL887880 | 0.76 | PDPK1 (0.51) | ADORA2AADORA1HSP90AA1PDPK1 | |
| SCHEMBL14002419 | 0.75 | CYP2A6 (0.38) | ADORA2AADORA1KDM4AKDM4BKDM5C | |
| SCHEMBL540121 | 0.75 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2BKDM5B | |
| SCHEMBL14002404 | 0.72 | ADORA2A (0.41) | ADORA2AADORA1ADORA3ADORA2BKDM4A | |
| SCHEMBL30162844 | 0.70 | CHUK (0.48) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL2933188 | 0.70 | CHUK (0.48) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL16265999 | 0.70 | ADORA2A (0.41) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.69 | GDA (0.48) | ADORA2AADORA3ALDH1A1PDPK1 | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.69 | GDA (0.48) | ADORA2AADORA3ALDH1A1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401407-A1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | Kabushiki Kaisha Dnaform (JP) | 2018-11-14 | — | — | EP | claimed |
| US-10066264-B2 | Method for analyzing target nucleic acid, kit, and analyzer | KABUSHIKI KAISHA DNAFORM (JP) | 2018-09-04 | — | — | US | claimed |
| EP-2873731-B1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | DNAFORM KK (JP) | 2018-08-29 | — | — | EP | claimed |
| EP-2891714-B1 | METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER | DNAFORM KK (JP) | 2018-07-11 | — | — | EP | claimed |
| US-9862989-B2 | Nucleic acid probe, method for designing nucleic acid probe, and method for detecting target sequence | KABUSHIKI KAISHA DNAFORM (JP) | 2018-01-09 | — | — | US | claimed |
| US-20150203902-A1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | KABUSHIKI KAISHA DNAFORM (JP) | 2015-07-23 | — | — | US | claimed |
| EP-2891714-A1 | METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER | Kabushiki Kaisha Dnaform (JP) | 2015-07-08 | — | — | EP | claimed |
| US-20150152496-A1 | METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER | KABUSHIKI KAISHA DNAFORM (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2873731-A1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | Kabushiki Kaisha Dnaform (JP) | 2015-05-20 | — | — | EP | claimed |
| US-8067162-B2 | Replication; hybridization; kits | RIKEN (JP) | 2011-11-29 | — | — | US | claimed |
| US-10760116-B2 | Analysis kit, analyzer, and methods for analyzing template nucleic acid or target substance | KABUSHIKI KAISHA DNAFORM (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3339447-B1 | METHOD FOR ANALYZING TEMPLATE NUCLEIC ACID, METHOD FOR ANALYZING TARGET SUBSTANCE, ANALYSIS KIT FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE, AND ANALYZER FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE | DNAFORM KK (JP) | 2020-07-29 | — | — | EP | disclosed |
| EP-3401407-B1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | DNAFORM KK (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-10428371-B2 | Fluorescent labeled single-stranded nucleic acid and use thereof | KABUSHIKI KAISHA DNAFORM (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20190032108-A1 | METHOD FOR ANALYZING TEMPLATE NUCLEIC ACID, METHOD FOR ANALYZING TARGET SUBSTANCE, ANALYSIS KIT FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE, AND ANALYZER FOR TEMPLATE NUCLEIC ACID OR TARGET SUBSTANCE | RIKEN (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | RIKEN (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20080227104-A1 | Replication; hybridization; kits | RIKEN (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1970453-A2 | Primer, primer set, and nucleic acid amplification method and mutation detection method using the same | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1816130-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF | Riken (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | DUT, NT5C3B, NT5C | ADORA2A 889/4885ADORA1 1454/4885HSP90AA1 4193/4885 |
| US-20080227104-A1 | Replication; hybridization; kits | PCNA, POLL, RNGTT | ADORA2A 4447/4885ADORA1 2969/4885HSP90AA1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.